Skip to main content
Clinical Trials/NCT00398996
NCT00398996
Completed
Phase 3

Study to Compare Three Existing Starting Points of ART Initiation in HIV/TB Co-infected Patients

Centre for the AIDS Programme of Research in South Africa1 site in 1 country642 target enrollmentJune 2005

Overview

Phase
Phase 3
Intervention
Early versus intermediate versus late initiation of ART
Conditions
HIV Infections
Sponsor
Centre for the AIDS Programme of Research in South Africa
Enrollment
642
Locations
1
Primary Endpoint
To measure the incidence of progression to AIDS defining illness or mortality
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

This is a randomized, open-label study comparing three existing treatment strategies of ART initiation in HIV/TB co-infected patients:

Group 1: early initiation of ART with TB treatment, Group 2: initiation of ART upon completion of the intensive phase of TB treatment, Group 3: initiation of ART upon completion of the continuation phase of TB treatment

Approximately 700 men and women ≥ 18 years of age with documented HIV infection and smear-positive pulmonary TB patients will be enrolled. Eligible TB/HIV co-infected patients will be offered antiretroviral therapy (ART), starting at one of the three time points listed above through the CAPRISA AIDS treatment programme which includes extensive counselling and adherence support. The study participants will be followed for 18 months to assess the primary study endpoint of the optimal time to start antiretroviral therapy (ART) in patients on tuberculosis (TB) treatment by comparing clinical status (CD4+ cell count, viral load, opportunistic infections.

Registry
clinicaltrials.gov
Start Date
June 2005
End Date
July 2010
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • HIV infected patients co-infected with TB
  • Receiving any one of the standard anti-TB therapy regimens
  • All patients must agree to use contraception since they will be on efavirenz.

Exclusion Criteria

  • Entry into the treatment programme is based on a clinical assessment and should patients not be clinically eligible to maintain a treatment regimen,their entry may be deferred or precluded

Arms & Interventions

1 - Early integrated-therapy group

antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment

Intervention: Early versus intermediate versus late initiation of ART

2 - Late integrated-therapy group

antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment

Intervention: Early versus intermediate versus late initiation of ART

3 - Sequential-therapy group

Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment

Intervention: Early versus intermediate versus late initiation of ART

Outcomes

Primary Outcomes

To measure the incidence of progression to AIDS defining illness or mortality

Time Frame: 18 months

Secondary Outcomes

  • A comparison of CD4+ cell count, viral load, opportunistic infections across the 3 study arms(18 months)

Study Sites (1)

Loading locations...

Similar Trials